| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Immunovant, Inc. | Chief Financial Officer | Common Stock | 208K | $3.06M | $14.68 | May 1, 2025 | Direct |
| Immunovant, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 294K | May 1, 2025 | Direct | ||
| Landos Biopharma, Inc. | Director | Stock Option (right to buy) | 0 | May 23, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | May 1, 2025 | 2 | $0 | 4 | May 5, 2025 | Chief Financial Officer |
| IMVT | Immunovant, Inc. | Apr 21, 2025 | 0 | $0 | 3 | Apr 28, 2025 | Chief Financial Officer |
| LABP | Landos Biopharma, Inc. | May 23, 2024 | 3 | $0 | 4 | May 23, 2024 | Director |
| LABP | Landos Biopharma, Inc. | May 23, 2023 | 1 | $0 | 4 | May 24, 2023 | Director |
| LABP | Landos Biopharma, Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
| LABP | Landos Biopharma, Inc. | May 16, 2022 | 1 | $0 | 4 | May 18, 2022 | Director |